Liping D. Wang

No. 1 Jianshe East Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety.

Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety.

Journal: Frontiers in oncology

Published: March 04, 2026

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.

Journal: Journal of translational medicine

Published: July 22, 2025

Relationships Between Insomnia and Quality of Life in Patients With Advanced Liver Cancer: A Secondary Analysis of a Multicenter Cross-Sectional Study.

Relationships Between Insomnia and Quality of Life in Patients With Advanced Liver Cancer: A Secondary Analysis of a Multicenter Cross-Sectional Study.

Journal: Psycho-oncology

Published: December 23, 2024

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.

Journal: Journal for immunotherapy of cancer

Published: November 17, 2024

Prognostic models of immune-related cell death and stress unveil mechanisms driving macrophage phenotypic evolution in colorectal cancer.

Prognostic models of immune-related cell death and stress unveil mechanisms driving macrophage phenotypic evolution in colorectal cancer.

Journal: Journal of translational medicine

Published: November 06, 2024

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Journal: Journal for immunotherapy of cancer

Published: October 10, 2024

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy.

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy.

Journal: Frontiers in oncology

Published: August 25, 2024

Development of a prediction model for suicidal ideation in patients with advanced cancer: A multicenter, real-world, pan-cancer study in China.

Development of a prediction model for suicidal ideation in patients with advanced cancer: A multicenter, real-world, pan-cancer study in China.

Journal: Cancer medicine

Published: March 09, 2024

Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer.

Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: February 21, 2024

PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.

PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 13, 2024

Suicidal ideation in Chinese patients with advanced breast cancer: a multi-center mediation model study.

Suicidal ideation in Chinese patients with advanced breast cancer: a multi-center mediation model study.

Journal: BMC psychology

Published: December 05, 2023

Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis'.

Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis'.

Journal: Journal for immunotherapy of cancer

Published: December 04, 2023

Showing 1-12 of 109

Last Updated: 09/26/2026